Follicular lymphoma relapses repeatedly, and each line of therapy narrows the options that remain. Lunsumio (mosunetuzumab) brought off-the-shelf T-cell engagement to that setting.
It binds CD20 on lymphoma cells and CD3 on T cells, redirecting the immune system to destroy them. Given as a fixed-duration intravenous course with step-up dosing, it treats adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma, after two or more lines of systemic therapy.
Its accelerated approval remains ongoing. The fixed-duration, treatment-free-interval design differentiates it from continuous therapy and from CAR-T manufacturing requirements, while competition from other CD20 bispecifics makes outpatient step-up feasibility a key practical differentiator.
